Eupraxia Pharmaceuticals (TSX:EPRX) Dividends Paid

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSX:EPRX Eupraxia Pharmaceuticals Inc TSX:EPRX
36 GF Score
Price C$12.10
! 2 Warning Signs
View Full Analysis

What is Eupraxia Pharmaceuticals Dividends Paid?

Dividends Paid only applicable to companies reporting Cash Flow from Operations in direct method.

TSX:EPRX
36GF Score
Eupraxia Pharmaceuticals Inc TSX:EPRX
Dividends Paid is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Eupraxia Pharmaceuticals Business Description

Other Exchanges EPRX:USAX43:Germany
Address 201 2067 Cadboro Bay Road, Victoria, BC, CAN, V8R 5G4
Eupraxia Pharmaceuticals Inc. is a clinical-stage biotechnology company based in Canada that develops locally delivered, extended-release formulations of existing drugs. Its lead product candidate, EP-104, uses the company's proprietary Diffusphere technology to provide sustained drug release at the site of disease. EP-104 is being developed in two main programs: EP-104IAR for chronic knee osteoarthritis pain, which has completed a Phase 2b trial, and EP-104GI for eosinophilic esophagitis. The company targets specialty and hospital-based markets where localized, long-acting delivery may offer advantages over systemic administration. As a clinical-stage company, Eupraxia does not yet generate product revenue; it funds operations through equity financings, partnerships, and government or research grants, and its future revenue depends on regulatory approval and commercialization of its pipeline candidates.
36GF Score

Get the complete analysis for TSX:EPRX

Dividends Paid is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

C$12.10
Price